This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Radiation Therapy  • Surgery  • Surgical Interventions  • Urology  • Alert me on articles by topic  Social Bookmarking   What's this?

Arnaud Merglen, MD; Franz Schmidlin, MD; Gerald Fioretta, BSc; Helena M. Verkooijen, MD, PhD; Elisabetta Rapiti, MD, MPH; Roberto Zanetti, MD; Raymond Miralbell, MD; Christine Bouchardy, MD, MPH

Arch Intern Med. 2007;167(18):1944-1950.

Background  No clear guidelines exist for managing localized prostate cancer because clinical studies have not yet established which treatment provides the best long-term outcome. We assessed the effect of treatment on prostate cancer–specific mortality considering the determinants of treatment and prognosis.

Methods  The population-based cohort included all 844 patients having a diagnosis of localized prostate cancer between January 1, 1989, and December 31, 1998, in Geneva, Switzerland. Treatments included prostatectomy (n = 158), radiotherapy (n = 205), watchful waiting (n = 378), hormone therapy (n = 72), and other types of therapy (n = 31). We compared survival curves using the log-rank test. With multivariate Cox proportional hazards analysis and propensity score methods, we evaluated the independent effect of treatments on prostate cancer–specific mortality.

Results  Treatment options only slightly influenced 5-year prostate cancer–specific mortality but had an important effect on long-term mortality. Ten-year specific survival was 83% (95% confidence interval [CI], 73%-93%), 75% (95% CI, 67%-83%), and 72% (95% CI, 66%-80%) for patients who underwent surgery, radiotherapy, and watchful waiting, respectively (P < .001). At 10 years, patients treated with radiotherapy or watchful waiting had a significantly increased risk of death from prostate cancer compared with patients who underwent prostatectomy (multiadjusted hazard ratio, 2.3 [95% CI, 1.2-4.3] and 2.0 [95% CI, 1.1-3.8], respectively). The increased mortality associated with radiotherapy and watchful waiting was primarily observed in patients younger than 70 years and in patients with poorly differentiated tumors (Gleason score  7; reference, 1 [best]-10 [worst]). Patients who received hormone therapy alone already had an increased risk of prostate cancer–specific mortality at 5 years (hazard ratio, 3.5 [95% CI, 1.4-8.7]).

Conclusions  Our study results suggest that surgery offers the best chance of long-term prostate cancer–specific survival, in particular for younger patients and patients with poorly differentiated tumors. Until clinical trials provide conclusive evidence, physicians and patients should be informed of these results and their limitations.

Author Affiliations: Geneva Cancer Registry, Institute of Social and Preventive Medicine, Geneva University, Geneva, Switzerland (Drs Merglen, Verkooijen, Rapiti, and Bouchardy and Mr Fioretta); Department of Urology (Dr Schmidlin) and Radio-oncology Division (Dr Miralbell), Geneva University Hospitals, Geneva; Urological Center, Clinique des Grangettes, Geneva (Dr Schmidlin); Department of Community Occupational and Family Medicine, National University of Singapore (Dr Verkooijen); and Piedmont Cancer Registry, Center for Oncologic Prevention, University of Turin, Turin, Italy (Dr Zanetti).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

"Short- and Long-term Mortality With Localized Prostate Cancer": Errors and Omissions?
Mack Roach, III
Arch Intern Med. 2008;168(12):1351.
EXTRACT | FULL TEXT  

Prostate Cancer—Which Treatment to Choose?
Jarrod B. Adkison and Mark A. Ritter
Arch Intern Med. 2008;168(12):1352.
EXTRACT | FULL TEXT  

Radiotherapy Dose in the Treatment of Localized Prostate Cancer
Karl Mikael Kälkner
Arch Intern Med. 2008;168(12):1352-1353.
EXTRACT | FULL TEXT  

Radiotherapy Dose in the Treatment of Localized Prostate Cancer—Reply
Elisabetta Rapiti, Arnaud Merglen, and Christine Bouchardy
Arch Intern Med. 2008;168(12):1353.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

"Short- and Long-term Mortality With Localized Prostate Cancer": Errors and Omissions?
Roach
Arch Intern Med 2008;168:1351-1351.
FULL TEXT  

Prostate Cancer--Which Treatment to Choose?
Adkison and Ritter
Arch Intern Med 2008;168:1352-1352.
FULL TEXT  

Radiotherapy Dose in the Treatment of Localized Prostate Cancer--Reply
Rapiti et al.
Arch Intern Med 2008;168:1353-1353.
FULL TEXT  

Radiotherapy Dose in the Treatment of Localized Prostate Cancer
Kalkner
Arch Intern Med 2008;168:1352-1353.
FULL TEXT